Chasing the effects of pre-analytical confounders - A multicenter study on CSF-AD biomarkers

Frontiers in Neurology

Volumn 6, Issue JUL, 2015, Pages

  Leitão, Maria João ^a   Baldeiras, Inês ^a,b,c   Herukka, Sanna Kaisa ^d   Pikkarainen, Maria ^d   Leinonen, Ville ^d   Simonsen, Anja Hviid ^e   Perret Liaudet, Armand ^f,g,h   Fourier, Anthony ^f,g   Quadrio, Isabelle ^f,g   Veiga, Pedro Mota ⁱ   de Oliveira, Catarina Resende ^a,b,c  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^c UNIVERSITY OF COIMBRA   (Portugal)

^d KUOPIO UNIVERSITY HOSPITAL   (Finland)

^e University of Copenhagen   (Denmark)

^f HOSPICES CIVILS DE LYON   (France)

^g UNIVERSITÉ LYON 1   (France)

^h Alzheimer Biomarkers Group Co Coordination   (France)

ⁱ Curva de Gauss Research   (Portugal)

Author keywords

Alzheimer's disease; BIOMARKAPD; Biomarkers; Cerebrospinal fluid; Phosphorylated tau protein; Standardized operating procedures; Tau protein; amyloid

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; PHOSPHORYLATED TAU PROTEIN; TAU PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; CENTRIFUGATION; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; DENMARK; FINLAND; FRANCE; FREEZE THAWING; HUMAN; MAJOR CLINICAL STUDY; MILD COGNITIVE IMPAIRMENT; PORTUGAL; PROTEIN CONTENT; STORAGE; TEMPERATURE;

EID: 84940025040     PISSN: None     EISSN: 16642295     Source Type: Journal    
DOI: 10.3389/fneur.2015.00153     Document Type: Article

References (34)

1. Blennow K. Cerebrospinal fluid protein biomarkers for Alzheimer's disease. NeuroRx (2004) 1:213-25. doi: 10.1602/neurorx.1.2.213
2. Rosén C, Hansson O, Blennow K, Zetterberg H. Fluid biomarkers in Alzheimer's disease - current concepts. Mol Neurodegener (2013) 8:20. doi:10.1186/1750-1326-8-20
3. Buchhave P, Blennow K, Zetterberg H, Stomrud E, Londos E, Andreasen N, et al. Longitudinal study of CSF biomarkers in patients with Alzheimer's disease. PLoS One (2009) 25(4):583-94. doi:10.1371/journal.pone.0006294
4. Baldeiras I, Santana I, Santiago B, Correia H, Ribeiro MH, Lemos R, et al. Cerebrospinal fluid biomarkers in frontotemporal lobar degeneration. J Neurol (2011) 258:S183-4.
5. Baldeiras I, Santana I, Ribeiro MH, Pascoal R, Lemos R, Santiago B, et al. Utility of cerebrospinal fluid markers in mild cognitive impairment. Neurodegener Dis (2011) 8(S1-11):486.
6. Herukka S-K, Hallikainen M, Soininen H, Pirttilä T. CSF Abeta42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment. Neurology (2005) 64(7):1294-7. doi:10.1212/01.WNL.0000156914.16988.56
7. Shaw LM, Soares H, Dean RA, Lilly E. Quantification of the analytical and clinical performance of CSF biomarker analyses in ADNI. Acta Neuropathol (2011) 121(5):597-609. doi:10.1007/s00401-011-0808-0
8. Hort J, Bartos A, Pirttilä T, Scheltens P. Use of cerebrospinal fluid biomarkers in diagnosis of dementia across Europe. Eur J Neurol (2010) 17(1):90-6. doi:10.1111/j.1468-1331.2009.02753.x
9. Hölttä M, Hansson O, Andreasson U, Hertze J, Minthon L, Nägga K, et al. Evaluating amyloid-ß oligomers in cerebrospinal fluid as a biomarker for Alzheimer's disease. PLoS One (2013) 8(6):e66381. doi:10.1371/journal.pone.0066381
10. Anoop A, Singh PK, Jacob RS, Maji SK. CSF biomarkers for Alzheimer's disease diagnosis. Int J Alzheimers Dis (2010) 2010:606802. doi:10.4061/2010/606802
11. Blennow K, Zetterberg H, Minthon L, Lannfelt L, Strid S, Annas P, et al. Longitudinal stability of CSF biomarkers in Alzheimer's disease. Neurosci Lett (2007) 419(1):18-22. doi:10.1016/j.neulet.2007.03.064
12. Höglund K, Bogstedt A, Fabre S, Aziz A, Annas P, Basun H, et al. Longitudinal stability evaluation of biomarkers and their correlation in cerebrospinal fluid and plasma from patients with Alzheimer's disease. J Alzheimers Dis (2012) 32(4):939-47. doi:10.3233/JAD-2012-120976
13. Zimmermann R, Lelental N, Ganslandt O, Maler JM, Kornhuber J, Lewczuk P. Preanalytical sample handling and sample stability testing for the neurochemical dementia diagnostics. J Alzheimers Dis (2011) 25(4):739-45. doi:10.3233/JAD-2011-110212
14. Teunissen CE, Verwey NA, Kester MI, van Uffelen K, Blankenstein MA. Standardization of assay procedures for analysis of the CSF biomarkers amyloid ß((1-42)), tau, and phosphorylated tau in Alzheimer's disease: report of an international workshop. Int J Alzheimers Dis (2010) 2010:635053. doi:10.4061/2010/635053
15. Lewczuk P, Beck G, Ganslandt O, Esselmann H, Deisenhammer F, Regeniter A, et al. International quality control survey of neurochemical dementia diagnostics. Neurosci Lett (2006) 409(1):1-4. doi:10.1016/j.neulet.2006.07.009
16. Lewczuk P, Wiltfang J. Neurochemical dementia diagnostics: state of the art and research perspectives. Proteomics (2008) 8(6):1292-301. doi:10.1002/pmic.200700703
17. Mattsson N. CSF Biomarker Variability in the Alzheimer's Association Quality Control Program (2013). Available from: http://www.alzheimersanddementia.com/article/S1552-5260(13)00042-3/pdf
18. Mattsson N, Andreasson U, Persson S, Arai H, Batish SD, Bernardini S, et al. The Alzheimer's association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement (2011) 7(4):386.e-95.e. doi:10.1016/j.jalz.2011.05.2243
19. Vanderstichele H, Bibl M, Engelborghs S, Le Bastard N, Lewczuk P, Molinuevo JL, et al. Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's biomarkers standardization initiative. Alzheimers Dement (2012) 8(1):65-73. doi:10.1016/j.jalz.2011.07.004
20. Bateman RJ, Wen G, Morris JC, Holtzman DM. Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker. Neurology (2007) 68:666-9. doi:10.1212/01.wnl.0000256043.50901.e3
21. Perret-Liaudet A, Pelpel M, Tholance Y, Dumont B, Vanderstichele H, Zorzi W, et al. Risk of Alzheimer's disease biological misdiagnosis linked to cerebrospinal collection tubes. J Alzheimers Dis (2012) 31:13-20. doi:10.3233/JAD-2012-120361
22. Lewczuk P, Beck G, Esselmann H, Bruckmoser R, Zimmermann R, Fiszer M, et al. Effect of sample collection tubes on cerebrospinal fluid concentrations of tau proteins and amyloid beta peptides. Clin Chem (2006) 52(2):332-4. doi:10.1373/clinchem.2005.058776
23. Schipke CG, Jessen F, Teipel S, Luckhaus C, Wiltfang J, Esselmann H, et al. Long-term stability of Alzheimer's disease biomarker proteins in cerebrospinal fluid. J Alzheimers Dis (2011) 26:255-62. doi:10.3233/JAD-2011-110329
24. Simonsen AH, Bahl JMC, Danborg PB, Lindstrom V, Larsen SO, Grubb A, et al. Pre-analytical factors influencing the stability of cerebrospinal fluid proteins. J Neurosci Methods (2013) 215:234-40. doi:10.1016/j.jneumeth.2013.03.011
25. Kaiser E, Schönknecht P, Thomann PA, Hunt A, Schröder J. Influence of delayed CSF storage on concentrations of phospho-tau protein (181), total tau protein and beta-amyloid (1-42). Neurosci Lett (2007) 417(2):193-5. doi:10.1016/j.neulet.2007.02.045
26. Del Campo M, Mollenhauer B, Bertolotto A, Engelborghs S, Hampel H, Simonsen AH, et al. Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update. Biomark Med (2012) 6:419-30. doi:10.2217/bmm.12.46
27. Bjerke M, Portelius E, Minthon L, Wallin A, Anckarsäter H, Anckarsäter R, et al. Confounding factors influencing amyloid beta concentration in cerebrospinal fluid. Int J Alzheimers Dis (2010) 2010:986310. doi:10.4061/2010/986310
28. Toombs J, Paterson RW, Schott JM, Zetterberg H. Amyloid-beta 42 adsorption following serial tube transfer. Alzheimers Res Ther (2014) 6:5. doi:10.1186/alzrt236
29. Pica-Mendez AM, Tanen M, Dallob A, Tanaka W, Laterza OF. Nonspecific binding of Aß42 to polypropylene tubes and the effect of tween-20. Clin Chim Acta (2010) 411(21-22):1833. doi:10.1016/j.cca.2010.07.019
30. Schoonenboom NSM, Mulder C, Vanderstichele H, Van Elk E-J, Kok A, Van Kamp GJ, et al. Effects of processing and storage conditions on amyloid beta (1-42) and tau concentrations in cerebrospinal fluid: implications for use in clinical practice. Clin Chem (2005) 51(1):189-95. doi:10.1373/clinchem.2004.039735
31. Toombs J, Paterson RW, Lunn MP, Nicholas JM, Fox NC, Chapman MD, et al. Identification of an important potential confound in CSF AD studies: aliquot volume. Clin Chem Lab Med (2013) 51:2311-7. doi:10.1515/cclm-2013-0293
32. Mattsson N, Blennow K, Zetterberg H. Inter-Laboratory Variation in Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: United We Stand, Divided We Fall. Clinical Chemistry and Laboratory Medicine (2010). p. 603-7.
33. Vos SJB, Visser PJ, Verhey F, Aalten P, Knol D, Ramakers I, et al. Variability of CSF Alzheimer's disease biomarkers: implications for clinical practice. PLoS One (2014) 9(6):e100784. doi:10.1371/journal.pone.0100784
34. Teunissen CE, Tumani H, Engelborghs S, Mollenhauer B. Biobanking of CSF: international standardization to optimize biomarker development. Clin Biochem (2014) 47(4-5):288-92. doi:10.1016/j.clinbiochem.2013.12.024